Sexual Coercion in Breast Cancer Patients Treated With Luteinizing Hormone-Releasing Hormone Agonists (LHRHa )
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 79
- 试验地点
- 2
- 主要终点
- LHRHa
研究概览
简要总结
The use of luteinizing hormone-releasing hormone agonists(LHRHa) to suppress ovarian function is a common strategy for treating premenopausal, hormone receptor-positive breast cancer. However, this approach can lead to more severe and prolonged menopausal symptoms, which can further impact intimate relationships and sexual function. Sexual coercion, encompassing both overt and subtle forms of pressure, is a significant global public health concern that threatens individual well-being.
详细描述
Objective
The use of luteinizing hormone-releasing hormone agonists(LHRHa) to suppress ovarian function is a common strategy for treating premenopausal, hormone receptor-positive breast cancer. However, this approach can lead to more severe and prolonged menopausal symptoms, which can further impact intimate relationships and sexual function. Sexual coercion, encompassing both overt and subtle forms of pressure, is a significant global public health concern that threatens individual well-being.
Methods: This study is a randomized controlled study. In this study, the validated Turkish version of the Sexual Coercion in Intimate Relationship Scale was utilized to investigate whether patients receiving LHRHa therapy experienced higher rates of sexual sexual coercion compared to those taking tamoxifen. The study included 40 patients using LHRHa and 39 patients using tamoxifen. The instrument assessed partner sexual coercion across three subdomains: resource manipulation/sexual coercion, commitment manipulation, and defection threat.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Factorial
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •being over 18 years of age
- •willingness to participate in this study
- •having received treatment for breast cancer
- •having a history of breast cancer surgery
- •having an active relationship with a spouse or partner.
排除标准
- •having any neuropsychiatric disorder
- •having any mental illness
- •having a history of gynecological surgery
- •currently receiving active chemotherapy or less than 3 months since completing chemotherapy
- •receiving treatment for metastatic disease
- •The use of selective serotonin reuptake inhibitors
结局指标
主要结局
LHRHa
时间窗: for 10 months
It was examined whether patients receiving LHRHa treatment were exposed to sexual pressure.
Tamoxifen
时间窗: for 10 months
It was examined whether patients receiving tamoxifen treatment were exposed to sexual pressure.
次要结局
未报告次要终点
研究者
Canan Kas
PhD, MSc, RN, Assistant Professor
Kastamonu University